Low-dose intraoperative brachytherapy in soft tissue sarcomas involving neurovascular structure
- PMID: 16376446
- DOI: 10.1016/j.radonc.2005.12.002
Low-dose intraoperative brachytherapy in soft tissue sarcomas involving neurovascular structure
Abstract
Background and purpose: To evaluate intraoperative brachytherapy in the management of soft tissue sarcomas involving neurovascular structures, its impact on local control and complications.
Patients and methods: Between 01/1989 and 12/2002, 98 patients received an intraoperative implant in conjunction with conservative surgery. Brachytherapy was part of the initial treatment (79 cases) or performed in recurrent disease (19 cases). We studied primary sarcomas involving neurovascular structures treated with conservative surgery and intraoperative brachytherapy (n = 6) or intraoperative brachytherapy and external irradiation (n = 73). Conservative surgery was performed as first treatment (51 cases), after chemotherapy (21 cases) and after primary external radiation (seven cases). Brachytherapy was performed according to Paris system rules. Patients were loaded with Iridium 192 (64 cases) or connected to a Microselectron PDR (15 cases). Mean dose given by brachytherapy was 20 Gy. Mean dose given of external radiotherapy was 46 Gy.
Results: With a median follow-up of 58 months, 5-year actuarial survival was 69% and local free disease at 5 years was 90%. Acute side-effects occurred in 22/79 requiring surgical repair in 10 patients. Late side-effects occurred in 35/79. No patient required amputation for complications. Prognostic factors were studied for the occurrence of acute and late side-effects and local control.
Conclusions: Intraoperative brachytherapy is efficient with excellent local control rates in soft tissue sarcomas presenting with neurovascular involvement and offers an acceptable conservative option.
Similar articles
-
Nerve tolerance to high-dose-rate brachytherapy in patients with soft tissue sarcoma: a retrospective study.BMC Cancer. 2005 Jul 19;5:79. doi: 10.1186/1471-2407-5-79. BMC Cancer. 2005. PMID: 16026629 Free PMC article.
-
Re-resection with brachytherapy for locally recurrent soft tissue sarcoma arising in a previously radiated field.Cancer J Sci Am. 1999 Jan-Feb;5(1):26-33. Cancer J Sci Am. 1999. PMID: 10188058
-
High-dose-rate intraoperative brachytherapy (IOHDR) using flab technique in the treatment of soft tissue sarcomas.Strahlenther Onkol. 2003 Jul;179(7):480-5. doi: 10.1007/s00066-003-1063-7. Strahlenther Onkol. 2003. PMID: 12835885
-
[Brachytherapy for soft tissue sarcomas. Technique and therapeutic indications].Cancer Radiother. 2006 Feb-Mar;10(1-2):63-7. doi: 10.1016/j.canrad.2005.09.024. Epub 2005 Nov 23. Cancer Radiother. 2006. PMID: 16309939 Review. French.
-
Use of brachytherapy to preserve function in children with soft-tissue sarcomas.Oncology (Williston Park). 1999 Mar;13(3):361-69; discussion 369-70, 373-4. Oncology (Williston Park). 1999. PMID: 10204155 Review.
Cited by
-
The pedicled myocutaneous flap as a choice reconstructive technique for immediate adjuvant brachytherapy in sarcoma treatment.Curr Oncol. 2012 Dec;19(6):e491-5. doi: 10.3747/co.19.1141. Curr Oncol. 2012. PMID: 23300372 Free PMC article.
-
Intraoperative radiation therapy (IORT) in soft-tissue sarcoma.Radiat Oncol. 2017 Jan 19;12(1):20. doi: 10.1186/s13014-016-0751-2. Radiat Oncol. 2017. PMID: 28100249 Free PMC article. Review.
-
Intraoperative radiotherapy (IORT) combined with external beam radiotherapy (EBRT) for soft-tissue sarcomas--a retrospective evaluation of the Homburg experience in the years 1995-2007.Radiat Oncol. 2009 Aug 26;4:32. doi: 10.1186/1748-717X-4-32. Radiat Oncol. 2009. PMID: 19709420 Free PMC article.
-
Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.BMC Cancer. 2014 May 20;14:350. doi: 10.1186/1471-2407-14-350. BMC Cancer. 2014. PMID: 24885755 Free PMC article. Clinical Trial.
-
Neoadjuvant Radiotherapy-Related Wound Morbidity in Soft Tissue Sarcoma: Perspectives for Radioprotective Agents.Cancers (Basel). 2020 Aug 12;12(8):2258. doi: 10.3390/cancers12082258. Cancers (Basel). 2020. PMID: 32806601 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical